What is the efficacy of ferric pyrophosphate (Triferic) for iron replacement in anemia of chronic disease and renal failure?

Updated: Nov 27, 2018
  • Author: Edgar V Lerma, MD, FACP, FASN, FAHA, FASH, FNLA, FNKF; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

In January 2015, the FDA approved ferric pyrophosphate (Triferic), a soluble iron replacement therapy, which is added to the hemodialysate solution. Approval was based on the PRIME study that showed soluble ferric pyrophosphate to be erythropoiesis-stimulator agent (ESA) sparing. Patients (n=103) were randomized to receive ferric pyrophosphate in dialysate or standard dialysate. The researchers found that ferric pyrophosphate was able to maintain hemoglobin and not increase ferritin, while significantly reducing the use of ESAs by 37.1% compared with regular dialysate.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!